New research indicates that people with cardiovascular-kidney-metabolic syndrome may have a higher risk of developing ...
In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback